Skip to main content

Table 2 Univerate analysis of medication use, dose, and maximum dose achieved and risk of SRC

From: Systemic sclerosis medications and risk of scleroderma renal crisis

 SRC (n = 31)SSc without SRC (n = 322)P-Value
Medication Use
 ACE Inhibitor77 (24/31)33 (108/332)< 0.001
 ARB13 (4/31)16 (53/322)NS
 ACE inhibitor or ARB84 (26/31)40 (128/322)< 0.001
 CCB (dihydropyridine)65 (20/31)66 (214/322)NS
 CCB (non-dihydropyridine)6 (2/31)4 (322)NS
 CCB (any)65 (20/31)70 (226/322)NS
 Endothelin Receptor Blocker (ERB)6 (2/31)3 (9/322)NS
 Mycophenolic Mofetil (MMF)16 (5/31)11 (36/322)NS
 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)84 (26/31)77 (249/322)NS
 Fluticasone42 (13/31)56 (180/322)NS
Doubling of Dose
 ACE Inhibitor61 (19/31)12 (38/322)P < 0.001
 ARB3 (1/31)3 (10/322)NS
 ACE inhibitor or ARB61 (19/31)14 (45/322)NS
 CCB (dihydropyridine)32 (10/31)23 (73/322)NS
 CCB (non-dihydropyridine)0 (0/31)3 (10/322)NS
 CCB (any)32 (10/31)25 (80/322)NS
Achieve Max Dose
 ACE Inhibitor45 (14/31)4 (14/322)< 0.001
 ARB10 (3/31)2 (8/322)0.06
 ACE inhibitor or ARB45 (19/31)7 (21/322)< 0.001
 CCB (dihydropyridine)19 (6/31)16 (50/322)NS
 CCB (non-dihydropyridine)3 (1/31)3 (10/322)NS
 CCB (any)19 (6/31)16 (52/322)NS